🇺🇸 FDA
Patent

US 9127274

Serpinc1 iRNA compositions and methods of use thereof

granted A61KA61K31/713A61P

Quick answer

US patent 9127274 (Serpinc1 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
62
CPC classes
A61K, A61K31/713, A61P, A61P43/00, A61P7/04